Matches 1 - 50 out of 52 1 2 >


Match Document Document Title
DE202009019116U1 Aqueous pharmaceutical compositions containing the borate-polyol complexes  
Ophthalmic multidose composition which is designed as a drop for topical administration directly into the eye, comprising: a first polyol, the first polyol is selected from mannitol, sorbitol or a...
DE202012013349U1 Improvements in and concerning compositions  
An aqueous solution in a single unit dosage, comprising (or consisting essentially of the) the following components: (a) 350 to 600 g / l PEG having an average molecular weight of 2500-4500 Da;...
DE102014205475A1 Polypropylene glycols having an antimicrobial effect in cosmetic or dermatological preparations  
The invention includes antimicrobial stable cosmetic or dermatological preparations with polypropylene glycols.
DE102013021019B4 Solid compositions consisting of beta-cyclodextrin and polyethylene glycol, mixtures thereof with polyethylene glycols, to processes for the production of moldings and uses  
Solid mass, consisting of β-cyclodextrin and polyethylene glycol of the general composition (Β-cyclodextrin)n × HO-X [OX]m-OH n = 0.5 to 2, and m = 4-9 and X = -CH2-CH2- And their mixtures of...
DE102013021019A1 Decontaminating skin of cresols with cyclodextrin-polyethylene glycol-containing products  
A mixture of polyethylene and / or polypropylene glycol and> 20% by weight of an adduct of β-cyclodextrin-polyethylene glycol is suitable to decontaminate human skin or mucosa of organic hazardous...
DE102013001151A1 Nasal preparation, used to topical, protective, nurturing/supporting application to treat irritation/swelling in nasal mucosa due to e.g. allergies, includes mineral salt, water, alcohols, poloxamer surfactants, and additives e.g. enzyme  
Nasal preparation comprises: 0.5-4 wt.% of mineral salt having at least 70 wt.%, based on the salt mixture, of sodium chloride salt as a main active ingredient comprising table salt, rock salt and...
DE102012000976A1 Composition for the topical treatment  
The present invention is a pharmaceutical composition in the form of a solid dosage, which is particularly suitable for the topical treatment of inflammatory diseases of the mouth and throat,...
DE102011088934A1 Drug combinations of one or more polyols and one or more physiologically acceptable hydroxamic acids, as well as cosmetic or dermatological preparations 10, such active ingredient combinations  
Active compound combinations comprising a) one or more polyols and b) one or more physiologically acceptable hydroxamic acids.
DE202013000748U1 A sprayable liquid composition for nasal administration in particular with increased local residence  
Dripping or sprayable liquid at room temperature, gelling in the application Nasalzubereitung comprising, and preferably consisting of: 0.5 to 4 wt .-% mineral salt having at least 70% wt .-%,...
DE102011077040A1 Active substance combinations of A-polylysine (epsilon-polylysine) and one or mehrerenethoxylierten and / or propoxylated alkanols  
Active compound combinations comprising: a) ε-polylysine (Epsilon-polylysine) b) one or more ethoxylated or propoxylated alkanols of the general formula in which R1 Hydrogen or a methyl group R2 a...
DE102009029717A1 Medical product, useful for post-surgical adhesion prophylaxis and/or hemostasis, comprises physically crosslinked polyvinyl alcohol and at least one biocompatible nucleating agent  
Medical product comprises physically crosslinked polyvinyl alcohol and at least one biocompatible nucleating agent. An independent claim is included for method for producing the medical product...
DE202010012256U1 laxative  
The invention relates to a laxative with improved compliance, containing polyethylene glycol (PEG). A medicinal product according to the invention is suitable for treating chronic obstipations and...
DE102006049821A1 New, well tolerated metal chelates, for use as radiodiagnostic, radiotherapeutic or NMR and X-ray diagnostic agents, contain chelator and perfluorinated polyethylene glycol residues  
New metal chelates (I) (optionally in salt form) contain (a) perfluorinated polyethylene glycol (PEG) residue(s), (b) chelator residue(s) and (c) at least one equivalent of metal(s) of atomic...
DE20321510U1 Kolonreinigungszusammensetzungen  
A dry composition for admixture with water wherein the dry Composition the following components per liter to be manufactured aqueous solution includes: a) 80 to 350 g of polyethylene glycol, b) 3...
DE102005059050A1 Cosmetic-/pharmaceutical composition, useful as hair treatment agent, hair wax or gel wax, and for modeling and/or forming a hairstyle, comprises hydrophobically modified polyol, polysaccharide, emulsifying agent, and fat material  
Cosmetic- or pharmaceutical composition comprises at least one hydrophobically modified polyols (up to 5 wt.%), at least one polysaccharide (up to 5 wt.%), at least one emulsifying agent (up to 25...
DE102005023799A1 Aqueous dispersions of water-soluble and / or water-swellable anionic polymers, process for their preparation and their use  
Aqueous dispersions of water-soluble and / or water-swellable anionic polymers which are available by free-radical polymerization of ethylenically unsaturated, anionic monomers in an aqueous...
DE102005022021A1 Isoalkane mixture, useful in hydrophobic component of homogenous/heterogeneous phase of cosmetic or pharmaceutical composition e.g. skin protectant, decorative cosmetic and hair treatment agent for damp bearing of skin  
Isoalkane mixture exhibits 1>H-NMR-spectrum with a chemical shift (delta ) of 0.6-1 ppm, related to tetramethylsilane, and a surface integral of 25-70%, related to the total integral surface....
DE20221551U1 Oil/water emulsion of lipophilic, unsaturated cosmetic agent, used in cosmetic or dermatological formulation for treating skin damaged by UV light and aging, contains glucose derivative and di- or poly-glycerol or ester as emulsifiers  
An oil/water (O/W) emulsion comprises an emulsifier which is a mixture of surfactant(s) (I) selected from glucose derivatives; surfactant(s) (II) selected from di- and poly-glycerols and their...
DE102004023288A1 Macrogol preparation  
The This invention relates to an active substance-containing Macrogol as Preparation, characterized in that the active ingredient in admixture with a or more in developing water gas excipients in...
DE10362135B4 Composition for treating fish infections comprises polyethylene glycol and a water-insoluble active ingredient  
Composition for treating fish infections caused by flatworms (especially skin and gill flukes and tapeworms), acanthocephala, parasitic nematodes, crustacea, myxozoa, protozoa, bacteria, fungi and...
DE10204696A1 Intranasal formulation, useful for the treatment and/or prophylaxis of acute rhinitis, colds and/or sinusitis, comprises polyethylene glycol as an inhibitor of viral adhesion to the intercellular adhesion molecule 1 receptor  
A formulation (A), containing at least one polyethylene glycol (PEG), useful for the treatment and/or prophylaxis of acute rhinitis, colds and/or sinusitis.
DE10204819A1 Hemostatic and its provision for medicine  
The invention relates to a haemostatic agent comprising at least one porous polyvinyl alcohol (PVA) in solid form, selected from the group consisting of uncross-linked PVA with a molecular weight...
DE10161149A1 Synergistic composition, useful for the treatment of ophthalmological dysfunction, e.g. allergic conjunctivitis, comprises mucopolysaccharide with heparin activity and viscosity regulator, preferably hyaluronic acid  
New pharmaceutical compositions (I) comprise: (1) at least one mucopolysaccharide with heparin activity (A); (2) at least one viscosity regulator (B); and (3) optionally, further pharmaceutical...
DE10161149B4 Use of heparin-containing ophthalmic preparation  
use of at least one pharmacologically compatible viscosity regulator and at least one mucopolysaccharide with heparin activity and optionally additional pharmaceutical aids for the manufacture of...
DE10117099A1 Medical Device, method for its preparation and provision for surgery  
A medical product for adhesion prophylaxis for postoperative prevention of adhesions in the body comprises at least one polyvinyl alcohol selected from the group consisting of uncrosslinked PVA...
DE10000807A1 A method for the treatment of a cosmetic composition by irradiation with NIR radiation, and its use  
The present invention relates to a method for the treatment of a cosmetic product, characterized in that the cosmetic product before, during or after the application is treated with NIR radiation.
DE19959119A1 emulsions  
There are emulsions claimed containing oligoesters as emulsifiers. These oligoesters have been used only as a so-called soil release polymers (soil release polymer).
DE19942365A1 Bulking agent based on three dimensional polymer network useful in stimulation of bowel activity and normalization of bowel evacuation  
Agent for stimulating bowel activity and/or for improving and/or normalizing defecation comprises a three dimensional spongy polymer network which, when it is degraded in the stomach or small...
DE19940130A1 New effectors of dipeptidyl peptidase IV for topical use  
The invention relates to compounds of general formula (I), wherein A represents an amino acid with at least one functional group in the side chain; while B is a chemical compound covalently bound...
DE19921794A1 New pharmaceutical composition  
The invention relates to a pharmaceutical composition, containing a combination of at least one antimycotic, polydocanol and optionally salicylic acid as active components which is used for the...
DE19858891A1 Improved bone sealant  
The present invention relates to improved bone sealant for breastfeeding of local bleeding bone, which are characterized in that the bone sealant from a polyester oligomer, synthesized from...
DE19810012A1 Cosmetic and / or pharmaceutical preparations  
cosmetic and / or pharmaceutical formulations comprising DOLLAR A (a) are proposed 0.1 to 10 wt .-% polyolpoly-12-hydroxystearate, DOLLAR A (b) 0 to 10 wt .-% alkyl and / or alkenyl, DOLLAR A (c)...
DE19727362A1 Polymers of unsaturated Saccharidsäuren and derivatives thereof and copolymers thereof with ethylenically unsaturated compounds and methods for their preparation  
The present invention relates to new polymerisates of unsaturated saccharide acids (aldonic, uronic or arsenial acids) as well as to the salts or derivatives thereof, wherein said polymerisates...
DE19709763A1 Porous poly:hydroxy:carboxylate preparation  
Preparation of a porous polyhydroxycarboxylic acid of formula -OOC-C(R)2-n (I) involves solid phase conversion of a halocarboxylate of formula MOOC-C(R)2-X (II) to give (I) and a metal halide MX...
DE19549506C2 Pharmaceutical or diagnostic dosage form, esp. for ophthalmic use  
Pharmaceutical or diagnostic dosage form comprises a water-repellent carrier supporting an attached lyophilisate which comprises a pharmaceutical or diagnostic agent and a swellable or...
DE19633268A1 Polymers bile acid Resorptionsinhibitoren with simultaneous bile acid Adsorberwirkung  
Polymer bile acid resorption inhibitors with simultaneous bile acid adsorbing effect are disclosed, as well as a process for preparing the same, medicaments which contain these compounds and their...
DE19631084A1 Use of (meth) acrylic acid copolymers to increase the permeability of the mucosal  
(Meth)acrylic acid copolymers used to increase the permeability of mucous membranes contain as comonomers (meth)acrylic acid esters and/or other radically polymerisable monomers, the molar ratio...
DE19541815B4 Using a solution of polyethylene glycol in water as an aqueous rinse solution for the prevention or treatment of thick mucus that occurs in conjunction with radiotherapy and / or chemotherapy-induced disorders of the mucous membranes  
use a solution of polyethylene glycol in water as an aqueous rinsing solution for replacement of thick mucus, in conjunction with radiotherapy and / or chemotherapy-induced Diseases of the mucous...
DE19541815A1 Use of polyethylene glycol for the prevention or treatment of diseases of the mucous membranes  
The invention relates to the use of polyethylene glycol or mixtures containing polyethylene glycol for the prevention or treatment of diseases of the mucous membranes, caused by radiotherapy or...
DE19520237A1 Cosmetic or dermatological preparations comprising oligomers or polymers of alpha-hydroxycarboxylic acids  
Cosmetic or dermatological compositions that contain an effective amount of one or several dissolved or suspended oligomers, and/or polymers, and/or co-oligomers and/or co-polymers of one or...
DE4412612A1 Medical and veterinary use of synthetic humate prods.  
Use of synthetic humates (I), prepd. by oxidn. of polyhydric phenolic cpds., for prodn. of the following agents is new: (a) agents with activity in the mucosal region; (b) orally administrable...
DE4412613A1 Medical and veterinary use of synthetic humate prods.  
Use of synthetic humates (I), prepd. by oxidn. of polyhydric phenolic cpds., for prodn. of the following agents is new: (a) agents with activity in the mucosal region; (b) orally administrable...
DE4340484A1 Compsn. contg. mucosally absorbed alkali or ammonium humate  
Oral compsn. having activity in gastric and intestinal mucous membranes contains a synthetic, water-soluble alkali or ammonium humate (I) having a mol.wt. up to 50000 D and obtd. by oxidn. of...
DE4329648A1 Use of polyvinyl ethers as germicides (microbicides)  
The invention relates to the use of polyvinyl ethers of the general formula in which R represents an alkyl group having 1 to 20 C atoms as germicides.
DE4226217A1 Treatment of "dry nose" using a surfactant - opt. combined with preservatives and/or bactericides and fungicides in physiological saline, to regulate the moisture content of nose and throat  
A surfactant opt. in combination with a preservative and/or a substance which acts as a bactericide or fungicide on the mucous membranes in physiological saline, can be used to treat "dry nose"....
DE4112489A1 Use of copolymer from D,L-lactide and lactone or hydroxybutyric acid  
Copolymers (I) from (A) D, L-lactide and (B) epsilon-caprolactone, delta-valerolactone, gamma-decalactone or beta-hydroxybutyric acid are used for the topical treatment of human and animal skin....
DE4035682A1 local anesthetic  
Disclosed are mixtures of homologous lauryl polyglycol ethers of the formula: C12H25O(CH2-CH2O)x-H in which C12H25 is a straight-chain primary alkyl group and x has a mean value of 5 to 7. The...
DE3922555A1 Medical use of polyethylene glycol compsns. - for eliminating harmful substances from the body  
(A) Solid or liq. oral dosage forms, e.g. tablets, pills, capsules, powders, syrups or solns., contg. polyethylene glycol (PEG) with a molecular wt. of up to 35,000 are used to dissolve and...
DE3917109A1 Compsns. for controlling snoring - contg. surfactant and preservative  
Anti-snoring compsns. containa 0.02-2 wt.% of a surfactant (I) and 0.002-0.5 wt.% of a preservative (II), opt. together with a microbicide (III), a buffer (IV) and an antioxidant (V). (I) is pref....
DE3928933A1 Periodontal REGENERATION MATERIALS  
A periodontium-regenerating material for the regenerative treatment of the periodontium consists of bio-degradable/absorbable copolymers of lactide/???-caprolactone or lactide/glycolide having a...

Matches 1 - 50 out of 52 1 2 >